Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020

Drug Safety(2024)10.1007/s40264-024-01443-3Source: DataRank Database

Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020 is a research paper published in Drug Safety (2024). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.09)OA: greenTopics (50)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Ameet Sarpatwari ORCID,Krista F. Huybrechts ORCID,Joyce Lii,Su Been Lee ORCID,Gita A. Toyserkani ORCID

Live enrichment

PubMed:38755509 PMC:PMC11324373 OpenAlex:https://openalex.org/W4396951188

Center for Drug Evaluation and Research

Grant: 75F40120C0044

National Institutes of Health

Grant: K01AG068365

National Institutes of Health

Grant: 5K01AG068365-03

Novel approaches to identify and quantify the impact of drug-drug interactions in older adults with diabetes, with a focus on multimorbidity and polypharmacy

Arnold Ventures

FWCI

1.09

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

greenLicense: Springer Nature TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11324373/pdf/nihms-2008018.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s40264-024-01443-3.pdf

publisherhttps://link.springer.com/article/10.1007/s40264-024-01443-3/fulltext.html

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11324373

Fields of Study

Cancer Risks and FactorsPregnancy and Medication ImpactMultiple Myeloma Research and TreatmentsMedicine03 medical and health sciences0302 clinical medicineHumansThalidomideLenalidomideFemaleUnited StatesPregnancyMiddle AgedAdultRisk Evaluation and MitigationMultiple MyelomaUnited States Food and Drug AdministrationAgedDatabases, Factual

MeSH Terms

Risk Evaluation and MitigationLenalidomideAdultAgedFemaleHumansMiddle AgedMultiple MyelomaPregnancyThalidomideUnited StatesUnited States Food and Drug AdministrationDatabases, Factual

Keywords

PomalidomideMedicineThalidomideLenalidomidePregnancyIntensive care medicineMultiple myelomaInternal medicineAdultDatabases, FactualUnited States Food and Drug AdministrationRisk Evaluation and MitigationMiddle AgedArticleUnited StatesHumansFemaleAged